Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Daniel Martín(Townsville Hospital), Frederick L. Ferris(National Institutes of Health), Maryann Redford(National Eye Institute), Juan E. Grunwald(University of Pennsylvania), Cynthia A. Toth(Duke University), Glenn J. Jaffe(Duke University), Maureen G. Maguire(Penn Presbyterian Medical Center), Stuart L. Fine(University of Colorado Denver), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine)
Cited by 1,709
Related Papers
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|857
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
|Ophthalmology|2016|702
Adalimumab in Patients with Active Noninfectious Uveitis
|New England Journal of Medicine|2016|646